Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 56, Issue 1, 2003, Pages 143-146

  Bittner, Beate ^a   González, Roberto Carlos Bravo ^a   Isel, Hughes ^a   Flament, Christophe ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cytochrome; Midazolam; P450 3A; Pharmacokinetics; Rat; Solutol HS 15

Indexed keywords

MIDAZOLAM; SOLUTOL HS 15;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; IN VIVO STUDY; LIVER BLOOD FLOW; MALE; NONHUMAN; PLASMA CLEARANCE; RAT;

EID: 0038692040     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(03)00041-9     Document Type: Article

References (14)

1. Ruchatz F., Schuch H. Physicochemical properties of Solutol HS 15 and its solubisates. BASF ExAct. 1:1998;6-7.
2. Reinhart T., Bauer K.H. The hemolysis and solubilization behavior of nonionic polymer surface-active agents classes. Pharmazie. 50:1995;407-408.
3. Leighton J.A., Bay M.K., Maldonado A.L., Johnson R.F., Schenker S. The effect of liver dysfunction on colchicine pharmacokinetics in rat. Hepatology. 11:1990;210-215.
4. Desrayaud S., Guntz P., Scherrmann J.M., Lemaire M. Effect of the p-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. 61:1997;153-163.
5. Tateishi T., Soucek P., Caraco Y., Guengerich P., Wood A.J.J. Colchicine biotransformation by human liver microsomes. Biochem. Pharmacol. 53:1997;111-116.
6. B. Bittner, R.C. Bravo González, I. Walter, M. Kapps, J. Huwyler, Impact of Solutol HS 15 on the pharmacokinetic behavior of colchicine upon intravenous administration to male Wistar rats, Biopharm. Drug Dispos., 24 (2003) 173-181.
7. Bravo González R.C., Mountfield R.J., Walter I., Delobel F., Bittner B. Impact of Solutol HS 15 on the clearance of midazolam in rat hepatocytes. Drug Metab. Rev. 33:2001;183.
8. Jacqz-Aigrain E., Daoud P., Burtin P., Desplanques L., Beaufils F. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet. 344:1994;646-650.
9. Ghosal A., Satoh H., Thomas P.E., Bush E., Moore D. Moore, Inhibition kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab. Dispos. 24:1996;940-947.
10. Ubeaud G., Schiller C.D., Hurbin F., Jaeck D., Coassolo P. Comparison of the stability of some major cytochrome P450 and conjugation reactions in rat, dog and human hepatocyte monolayers. Eur. J. Drug Metab. Pharmacokinet. 26:2001;37-45.
11. 't Hoen P.A.C., Bijsterbosch M.K., van Berkel T.J.C., Vermeulen N.P.E., Commandeur J.N.M. Midazolam is a phenobarbital-like cytochrome P450 inducer in rats. J. Pharm. Exp. Ther. 299:2001;921-927.
12. Cleton A., Mazee D., Voskuyl R.A., Danhof M. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br. J. Pharmacol. 127:1999;227-235.
13. Buszello K., Harnisch S., Müller R.H., Müller B.W. The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with Solutol HS 15. Eur. J. Pharm. Biopharm. 49:2000;143-149.
14. Lavé T., Dupin S., Schmitt C., Chou R.C., Jaeck D., Coassolo P. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application of 10 extensively metabolized drugs. J. Pharm. Sci. 86:1997;584-590.